Key clinical point:
Major finding: The median annualized bleeding rate was 0.00 days, regardless of whether patients received N8-GP every 4 days or every 7 days.
Study details: An extension of the phase 3 pathfinder 2 trial that involved 55 patients with two or fewer bleeding episodes during the preceding 6 months of the main trial.
Disclosures: The study was funded by Novo Nordisk. The investigators reported financial relationships with Bayer, CSL, Novo Nordisk, Octapharma, Genentech, Shire, and others.
Curry N et al. Haemophilia. 2019 Feb 28..